Praxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023. In the quarter to June 2026, revenue grew 1,349.1%, EPS grew 13.3% and free cash flow fell 43.5%, each against the same quarter a year earlier.
Follow PRAX
Praxis Precision Medicines, Inc. (PRAX) EV/Sales
As of 16 October 2026, Praxis Precision Medicines, Inc. (PRAX) trades at a EV/Sales of 735×. Over the past ten years it has ranged from 0.0× (December 2023) to 1,227× (August 2026); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 115× | 398.92% |
| FY2023 | 23.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 115× | (74.65%) |
| Sep 2024 | 455× | 90.10% |
| Jun 2024 | 239× | (13.58%) |
| Mar 2024 | 277× | 1,098.07% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.8× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 17.9× |
| LGND Ligand Pharmaceuticals Incorporated compare | 19.8× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 23.3× |
| PRAX Praxis Precision Medicines, Inc. | 735× |
| SYRE Spyre Therapeutics, Inc. compare | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)